1. Home
  2. BABA vs AMGN Comparison

BABA vs AMGN Comparison

Compare BABA & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alibaba Group Holding Limited

BABA

Alibaba Group Holding Limited

N/A

Current Price

$94.00

Market Cap

261.9B

ML Signal

N/A

Logo Amgen Inc.

AMGN

Amgen Inc.

N/A

Current Price

$465.66

Market Cap

251.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BABA
AMGN
Founded
1999
1980
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
261.9B
251.6B
IPO Year
2014
2002

Fundamental Metrics

Financial Performance
Metric
BABA
AMGN
Price
$94.00
$465.66
Analyst Decision
Strong Buy
Hold
Analyst Count
41
34
Target Price
$184.44
★ $431.81
AVG Volume (30 Days)
★ 7.8M
2.5M
Earning Date
11-19-2026
11-03-2026
Dividend Yield
1.11%
★ 2.16%
EPS Growth
N/A
★ 88.23
EPS
N/A
★ 14.79
Revenue
N/A
★ $25,424,000,000.00
Revenue This Year
$9.43
$7.41
Revenue Next Year
$12.74
$4.59
P/E Ratio
★ $21.20
$31.64
Revenue Growth
N/A
★ 8.83
52 Week Low
$91.99
$312.39
52 Week High
$181.10
$483.99

Technical Indicators

Market Signals
Indicator
BABA
AMGN
Relative Strength Index (RSI) 33.43 62.32
Support Level $91.99 $446.45
Resistance Level $112.00 $483.99
Average True Range (ATR) 2.44 11.64
MACD -0.54 -0.65
Stochastic Oscillator 5.10 60.28

Price Performance

Historical Comparison
BABA
AMGN

About BABA Alibaba Group Holding Limited

Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China retail e-commerce platform is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China wholesale e-commerce, international retail and wholesale e-commerce, local consumer services, travel services, cloud computing, digital media and entertainment, Cainiao logistics services, and other businesses.

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Share on Social Networks: